RecruitingNCT06711211

Spanish Registry of Digestive Tumours RETUD

A Descriptive, Multicentre, Observational Epidemiological Study on Digestive Tumours

Sponsor

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Enrollment

20,000 participants

Start Date

Dec 23, 2020

Study Type

OBSERVATIONAL

Conditions

Pancreatic Cancer Rectal Cancer Bile Duct Cancer Colorectal Cancer (CRC)Digestive Cancers Hepatocellular Cancer (HCC)

Summary

The aim of this observational study is to assess the current state of digestive tumours in Spain. By doing so, it seeks to enhance the quality of care, optimize the diagnosis and treatment of digestive tumours, and identify opportunities for improvement that can benefit patients. The study will investigate the epidemiological, biological, and clinical characteristics of digestive tumors diagnosed in patients aged 18 and older across healthcare centres in Spain. It also aims to generate knowledge and scientific evidence for events and situations that may impact on patients with digestive tumours (e.g. COVID-19 coronavirus pandemic). Furthermore, subject to the patient's consent, biological samples may be collected for use in translational research projects and for the identification of molecular markers that may be useful in healthcare decision-making.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is a Spanish national registry collecting data on patients with digestive tract cancers to better understand their treatments and outcomes over time. **You may be eligible if...** - You are 18 or older - You have been diagnosed with a digestive cancer, including: esophageal, stomach, pancreatic, liver (hepatocellular carcinoma), gallbladder or bile duct, small intestine, appendix, colorectal, anal canal, gastrointestinal stromal tumor (GIST), or hereditary digestive cancers - You can provide written informed consent **You may NOT be eligible if...** - The necessary information to complete the registry data cannot be obtained for you Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

Grupo de Tratamiento de los Tumores Digestivos (TTD)

Madrid, Madrid, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06711211

Related Trials

Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer

NCT0669845815 locations

Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer (Feasibility and Safety)

NCT056577432 locations

Alpha Radiation Emitters for the Treatment of Pancreatic Cancer for the Treatment of Locally Advanced Pancreatic Cancer

NCT060269431 location

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

NCT0500540346 locations

Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer

NCT019152251 location